Sensorion

Sensorion FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sensorion (ALSEN.PA) as of Oct 9, 2026 is 93.93 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.44 % — a change of 8.66% (higher).

FCF Conversion

93.93 %

YoY

8.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sensorion is 2025 93.93 % . FCF Conversion Rate (FCF/EBITDA) of Sensorion was 2024 86.44 % . It decreases by 8.66% higher compared to the previous year.

The Sensorion FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
99.30 EUR
Jan 1, 2019
117.75 EUR
Jan 1, 2020
61.03 EUR
Jan 1, 2021
78.05 EUR
Jan 1, 2022
98.75 EUR
Jan 1, 2023
99.44 EUR
Jan 1, 2024
86.44 EUR
Jan 1, 2025
93.93 EUR
The Sensorion FCF Conversion history
YEARFCF ConversionYoY
93.93 %+8.66%
86.44 %-13.07%
99.44 %+0.69%
98.75 %+26.52%
78.05 %+27.90%
61.03 %-48.17%
117.75 %+18.58%
99.30 %+21.05%
82.03 %-21.31%
104.24 %-14.56%
122.01 %+26.51%
96.44 %—
Access this data via the Eulerpool API

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

FCF Conversion Rate (FCF/EBITDA) of Sensorion is 93.93 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Sensorion changed from 86.44 % to 93.93 %, representing a 8.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sensorion since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sensorion with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Sensorion

All Key Metrics — Sensorion